剂量强化挽救性放疗对前列腺癌根治术后尿控恢复的影响:SAKK 09/10随机试验结果
在多中心随机试验中,生化复发前列腺癌患者接受64 Gy(32次)或70 Gy(35次)挽救性放疗,344例可评估。两臂在放疗后3个月新发尿失禁率均为14%,基线尿失禁患者尿控恢复率分别为44%和41%(p=0.8),剂量强化对早期尿控恢复无影响。
要点
- 剂量强化挽救性放疗未改善早期尿控恢复。
- 两臂放疗后3个月新发尿失禁率均为14%。
- 基线尿失禁患者3个月尿控恢复率64 Gy组44% vs 70 Gy组41%(p=0.8)。
核心结论
- 挽救性放疗剂量强化对早期尿控恢复或新发尿失禁率无影响。
研究设计与样本
- 多中心随机试验,纳入生化复发前列腺癌患者,分别接受64 Gy(32次)或70 Gy(35次)挽救性放疗,344例可评估。
主要发现
- 基线时233例(68%)患者完全尿控,两臂放疗后3个月新发尿失禁率均为14%。
- 基线尿失禁的111例(32%)患者中,放疗后3个月尿控恢复率64 Gy组为44%,70 Gy组为41%(p=0.8)。
临床怎么用
- 挽救性放疗剂量强化不影响早期尿控恢复,临床决策时无需因尿控顾虑而避免剂量强化。
局限性
- 分析受限于随访时间短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Adjuvant radiation therapy (aRT) after radical prostatectomy (RP) is associated with impaired urinary continence recovery as compared to surveillance. Less is known regarding the effect of salvage radiation therapy (sRT) dose intensification on continence outcomes. MATERIALS AND METHODS: Urinary continence recovery was investigated within a multicentre randomized trial in biochemically recurrent prostate cancer patients who received either 64 Gy (32 fractions) or 70 Gy (35 fractions) sRT. Incontinence was assessed using Common Toxicity Criteria for Adverse Events v4.0 at baseline, at the end of sRT and 3 months afterward. Quality of life (QoL) was assessed with the EORTC QoL questionnaires C30 and PR25 at baseline and 3 months after completion of sRT. A total of 344 patients were evaluable. RESULTS: At baseline 233 (68%) of patients were fully continent and 14% in both arms became incontinent three months after treatment. Of the remaining 111 (32%) patients being incontinent at baseline, continence recovery was achieved 3 months after sRT by 44% vs. 41% with 64 vs. 70 Gy, respectively (p = 0.8). This analysis is limited by its short follow-up. CONCLUSIONS: Dose intensification of sRT had no impact on early urinary continence recovery or prevalence of de novo incontinence.
引用
- Ghadjar P, Hayoz S, Bernhard J, et al. Impact of dose intensified salvage radiation therapy on urinary continence recovery after radical prostatectomy: Results of the randomized trial SAKK 09/10. Radiother Oncol. 2017. PMID: 29103826. doi:10.1016/j.radonc.2017.10.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。